Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurostimulation an extra bonus for Johnson & Johnson in Guidant deal

This article was originally published in Clinica

Executive Summary

Guidant's expertise in implantable micro-electronics, developed for use in pacemakers, has been untapped in other therapy fields. It looks like that could change. While the two clear attractions for Johnson & Johnson in its $25.4bn takeover deal for Guidant are the latter's cardiac rhythm management and stent delivery technologies, Guidant's know-how also lends itself to the as yet under-penetrated neurostimulation market, as its New Jersey-based acquirer has already acknowledged.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060570

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel